| abstract |
The present invention relates to a fusion protein comprising a non-cytotoxic protease and an EGF mutein ligand. EGF muteins provide improved EGF receptor activation for claimed fusion proteins. In addition, as a therapeutic method for suppressing cancer, such as colorectal cancer, prostate cancer, breast cancer, and lung cancer, to suppress mucus hypersecretion, inflammation, endocrine neoplasms and / or neuroendocrine disorders, neuroendocrine tumors Use of the polypeptide is provided. |